Recent Updates
Recently added Catalysts
CMPS Positive Sentiment Score: 60/100

Compass Pathways gibt am 5. August 2026 die Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2026 bekannt

Wednesday, July 29, 2026 1 min read
Key Takeaway: Compass Pathways plc has announced that it will release its financial results for Q2 and the first half of 2026 on August 5, 2026. The results will cover the period ending June 30, 2026. The management will hold a call to discuss these results, indicating their commitment to transparency.

Market Sentiment Analysis

POSITIVE FACTORS

  • Compass Pathways is focused on developing new treatment options for mental health.
  • The announcement of financial results indicates ongoing business activity.
  • The scheduled management call shows transparency and engagement with stakeholders.

Full Press Release Details

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), ein Biotechnologieunternehmen, das sich der Erschließung dringend benötigter neuer Behandlungsmöglichkeiten in der psychischen Gesundheitsversorgung verschrieben hat, gab heute bekannt, dass es am 5. August 2026 die Finanzergebnisse für das zweite Quartal und das erste Halbjahr, die am 30. Juni 2026 endeten, veröffentlichen wird. Das Management von Compass wird am 5. August 2026 um 8:00 Uhr ET (13:00 Uhr britischer Zeit) e

Frequently Asked Questions

When will Compass Pathways announce its financial results?

Compass Pathways will announce its financial results on August 5, 2026.

What period do the financial results cover?

The financial results will cover the period ending June 30, 2026.

What time will the management call take place?

The management call will take place at 8:00 AM ET on August 5, 2026.

Where is Compass Pathways based?

Compass Pathways is based in London and New York.

Tags: CMPS Viatris Investor Conferences Healthcare Compass Pathways financial results mental health biotechnology
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$466M liquidity · $16M/mo burn
~27 mo
Minimal dilution risk
Lead asset
PsilocybinPhase 3
Major Depressive Disorder →